Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma

Tibor A Zwimpfer; Hannah Ewald; Esra Bilir; Madawa Jayawardana; Christian Appenzeller-Herzog; Nicolò Bizzarri; Zoia Razumova; Joanna Kacperczyk-Bartnik; Viola Heinzelmann-Schwarz; Michael Friedlander; David Dl Bowtell; Dale W Garsed

doi:10.1002/14651858.CD015896

Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma

Cochrane Database Syst Rev. 2024 Sep 23;9(9):CD015896. doi: 10.1002/14651858.CD015896.

Authors

Tibor A Zwimpfer^{1

2}, Hannah Ewald³, Esra Bilir^{4

5

6}, Madawa Jayawardana^{1

7}, Christian Appenzeller-Herzog³, Nicolò Bizzarri⁸, Zoia Razumova⁹, Joanna Kacperczyk-Bartnik¹⁰, Viola Heinzelmann-Schwarz², Michael Friedlander¹¹, David Dl Bowtell^{1

7}, Dale W Garsed^{1

7}

Affiliations

¹ Peter MacCallum Cancer Centre, Melbourne, Australia.
² Gynaecological Cancer Centre, University Hospital Basel, Basel, Switzerland.
³ University Medical Library, University of Basel, Basel, Switzerland.
⁴ Department of Global Health, Koç University Graduate School of Health Sciences, Istanbul, Turkey.
⁵ Department of Gynecologic Oncology, Koc University School of Medicine, Istanbul, Turkey.
⁶ Department of Obstetrics and Gynecology, University Hospitals Schleswig-Holstein, Campus Kiel, Kiel, Germany.
⁷ Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
⁸ UOC Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
⁹ Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
¹⁰ Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland.
¹¹ Medical Oncology, Prince of Wales Hospital, Sydney, Australia.

PMID: 39312297
PMCID: PMC11418971 (available on 2025-09-23)
DOI: 10.1002/14651858.CD015896

Abstract

This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors.

MeSH terms

Cystadenocarcinoma, Serous / genetics
Cystadenocarcinoma, Serous / mortality
Fallopian Tube Neoplasms / drug therapy
Fallopian Tube Neoplasms / genetics
Fallopian Tube Neoplasms / mortality
Fallopian Tube Neoplasms / pathology
Female
Genes, BRCA1
Genes, BRCA2
Humans
Mutation
Ovarian Neoplasms* / genetics
Ovarian Neoplasms* / mortality
Prognosis
Progression-Free Survival